Preventing ovarian cancer in high-risk women
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests if removing the fallopian tubes (fimbriectomy) can lower the risk of ovarian or pelvic cancer in women with certain gene mutations. The goal is to find a less invasive prevention option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 35 and 50 years old.
- You have a gene mutation (like BRCA1, BRCA2, RAD51C, RAD51D, or PALB2) that raises your risk for ovarian or pelvic cancer.
- You have not had both ovaries or both fallopian tubes removed.
- You have never had ovarian, fallopian tube, or pelvic cancer.
- You are not in menopause (or if you are, you meet specific medical definitions).
- You can commit to follow-up visits and live in France with social security coverage.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This study looks at the safety of removing your fallopian tubes first (RRS) and delaying ovary removal (oophorectomy) to lower cancer risk. It focuses on women who carry certain inherited gene changes, and may help avoid earlier menopause for some people.
This study looks at removing fallopian tubes during other planned surgeries to help prevent ovarian cancer. You may be able to join if you are at least 45 years old, are female or assigned female at birth, and are having non-gynecologic surgery (like gallbladder or hernia repair).
This study looks at whether removing the fallopian tubes first, and the ovaries later, is safe for women with certain inherited gene mutations that raise ovarian cancer risk. It may help you understand a prevention approach when you’re considered high risk and have finished having children.
This trial tests a personalized vaccine made from your own immune cells, designed to target a protein called folate receptor alpha found on many ovarian cancer cells. It is for people who have finished initial chemotherapy and have no signs of cancer remaining, to try to prevent it from coming back.
This study follows women who carry gene mutations that increase ovarian cancer risk to understand how preventive surgery affects their health, quality of life, and peace of mind. Researchers will track your outcomes over 3 years to help inform future treatment decisions for others at similar risk.
Hear when a new High Grade Serous Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.